Jordi Casafont
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jordi Casafont.
Allergologia Et Immunopathologia | 2014
J. Ancochea; T. Chivato; P. Casan; César Picado; L. Herráez; Jordi Casafont
BACKGROUND Omalizumab is indicated in patients with severe allergic asthma not controlled by high-dose inhaled glucocorticoids and long-acting beta-agonists. Few data are available on the profile of patients treated with this drug in routine clinical practice in Spain. OBJECTIVE To describe the profile of patients with severe allergic asthma treated with omalizumab and the course of the disease after a period of treatment. METHODS Retrospective, multicentre study, recording the data on patients of either sex and ≥12 years with uncontrolled severe allergic asthma, previously treated with omalizumab. Data were evaluated in relation to pulmonary function, symptoms, quality of life, and concomitant anti-asthma treatment before the prescription of omalizumab and at the time of the study visit. RESULTS 214 patients were evaluable (mean age=48.2±17.7 years; mean age at the time of diagnosis=26.6±16.5 years). 90.7% had experienced exacerbations the year before receiving omalizumab, and the mean total IgE level was 273±205.4IU/ml. The mean monthly dose was 380.5±185.4mg. Compared with the baseline situation, differences were observed after treatment with omalizumab in mean FEV1 (62.7±15.9% vs. 70.8±18.7%), in the proportion of patients requiring oral corticosteroids (47.7% vs. 14.0%), and in the ACQ and AQLQ scores. 32.7% of the patients received doses not recommended by the Summary of Product Characteristics (SPC). CONCLUSIONS Profile of asthmatic patients treated with omalizumab predominantly corresponds to uncontrolled severe asthma cases, in accordance with SPCs indications. The results of the study suggest a favourable clinical course similar to that observed in other studies.
Archivos De Bronconeumologia | 2014
María del Carmen Vennera; César Picado; Lys Herráez; J. Galera; Jordi Casafont
INTRODUCTION Despite current treatments, more than half of patients with asthma are not controlled. The objective was to evaluate the correlation between control perceived by patients and physicians, compared with control evaluated according to criteria of the Spanish Guidelines for Asthma Management (GEMA), and to investigate the factors associated with that control. METHODS Multicenter, cross-sectional, observational study including 343 patients with severe persistent asthma according to GEMA criteria seen in the Department of Pulmonology and Allergology. The correlation between asthma control perceived by the patient, the physician and according to clinical judgment based on the GEMA criteria was calculated, and a multivariate analysis was used to determine variables related to the perception of asthma control. RESULTS According to GEMA criteria, only 10.2% of patients were well controlled, 27.7% had partial control and 62.1% were poorly controlled. Both the physicians and the patients overestimated control: 75.8% and 59.3% of patients had controlled asthma according to the patient and the physician, respectively, and were not controlled according to GEMA (P<.0001). Patients with uncontrolled asthma according GEMA had higher body mass index (P=.006) and physical inactivity (P=.016). Factors associated with a perceived lack of control by both physicians and patients were: nocturnal awakenings (≥ 1 day/week), frequent use of rescue medication (≥ 5 days/week) and significant limitation in activities. Discrepant factors between physicians and patients were dyspnea and emergency room visits (patients only), FEV1 ≤ 80% and a poorer understanding of the disease by the patient (physicians only). CONCLUSIONS Only 10% of patients with severe asthma evaluated in this study are controlled according to GEMA criteria. Patients and physicians overestimate control and the overestimation by patients is greater. Physical inactivity and obesity are associated with a lack of control according to GEMA.
Gaceta Sanitaria | 2006
Luis Borderias; Pilar García-Ortega; Xavier Badia; Jordi Casafont; Gemma Gambús; Montserrat Roset
OBJECTIVES To estimate the prevalence of diagnosis of allergic asthma in patients with persistent asthma attending allergy or pneumology outpatient clinics and to describe the clinical management of asthma in these patients. METHODS Systematic random sampling was used to retrospectively include 382 patients aged between 12 and 65 years old with a diagnosis of persistent asthma (according to GINA criteria) who had attended allergy or pneumology outpatient clinics during the previous year. Allergic asthma was defined as the presence of sensitization to any common allergen according to the results of specific IgE determinations and/or skin tests. Data on the treatment of asthma were gathered. RESULTS Allergy studies were performed in 99.5% of the patients attending allergy centers and in 76.5% of those attending pneumology centers. A diagnosis of allergic asthma was made in 90.6% (95% CI: 86.5-94.7) and 46.1% (95% CI: 39.0-53.2), respectively. The prevalence of allergic asthma was highest in young male patients with less severe asthma. According to the GINA criteria, 14.1% of patients from allergy centres and 23.0% of those from pneumology centers were classified as having severe persistent asthma. Twenty-four percent of patients attending allergy clinics and 5.7% of those attending pneumology centers received bronchodilator treatment exclusively. CONCLUSIONS Diagnosis of allergic asthma was much higher in allergy clinics than in pneumology centres. Although some of this difference may be due to more frequent performance of allergy studies in allergy clinics, the most probable explanation lies in the differences observed in the profiles of patients attending the two types of center.
Archivos De Bronconeumologia | 2014
María del Carmen Vennera; César Picado; Lys Herráez; J. Galera; Jordi Casafont
European Respiratory Journal | 2012
Emilia Jumbe Marsden; Somwe Wa Somwe; Chishala Chabala; Jordi Casafont; Joan B. Soriano; César Picado; Julio Ancochea
Value in Health | 2011
J. Galera; Raquel Lahoz; Lys Herráez; Jordi Casafont; A. Plaza; M. Vennera
Value in Health | 2011
J. Galera; R. Lahoz; Lys Herráez; Jordi Casafont; M. Vennera; C. Picado
European Respiratory Journal | 2011
Joan B. Soriano; Francisco García-Río; Marc Miravitlles; Myriam Calle-Rubio; Albert Jovell; Esteve Fernández; José Miguel Rodríguez González-Moro; Mª Carmen Montero; Mª Angeles Planchuelo; Jordi Casafont; Juan Ruiz-Manzano; Julio Ancochea
European Respiratory Journal | 2011
María del Carmen Vennera; César Picado; Lys Herráez; J. Galera; Jordi Casafont
European Respiratory Journal | 2011
María del Carmen Vennera; César Picado; Lys Herráez; J. Galera; Jordi Casafont